

Special Issue

Precision Approaches in the Diagnosis and Management of Inflammatory Bowel Disease

Message from the Guest Editor

Inflammatory bowel disease (IBD) is a chronic immune-mediated disorder of the gastrointestinal tract, marked by relapsing inflammation, unpredictable symptom patterns, and heterogeneous treatment responses. While current therapies have improved disease control, many patients experience only partial remission or develop treatment-related complications that affect long-term outcomes. In addition to intestinal inflammation, growing evidence highlights the broader systemic impact of IBD and its therapies, including increased risk of metabolic dysfunction, weight gain, insulin resistance, and hepatobiliary disease. These complications not only affect overall health but may also contribute to disease progression. Addressing these challenges requires more integrative and personalized approaches to care. Recent advances in noninvasive diagnostics, microbiome-targeted therapies, dietary interventions, and multi-omics profiling are transforming how we understand and manage IBD. Alongside these, clinical strategies such as therapeutic repurposing, combination treatments, personalized dosing, and biomarker-based decision-making are helping to drive a broader shift toward precision medicine.

Guest Editor

Dr. Jiayu Ye

Division of Gastroenterology and Hepatology, Stanford Medicine,
Stanford University, 300 Pasteur Dr., Palo Alto, CA 94305, USA

Deadline for manuscript submissions

28 February 2026



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/250660

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).